Neuroleptic malignant syndrome
Reading File
Finding Sources
Searching PubMed
"neuroleptic malignant syndrome" diagnosis treatment
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
Neuroleptic Malignant Syndrome (NMS)
Definition & Epidemiology
NMS is a rare but potentially fatal idiosyncratic complication of dopamine D2 receptor antagonism - not a dose-dependent toxicity. It is not the result of overdose; serum antipsychotic levels are typically within the therapeutic range when it occurs.
- Incidence: ~1-2 cases per 10,000 patients treated (some sources cite 0.2% of all patients receiving neuroleptics)
- Mortality: 15-30% if not recognized and treated promptly
- Demographics: More common in adult males, peak incidence ages 20-25
- Timing: Can occur days, weeks, or months after neuroleptic initiation, or after a dose adjustment
- Tintinalli's Emergency Medicine, p. 1252; Adams and Victor's Neurology, p. 1209
Causative Agents
Any dopamine D2 receptor blocking agent can precipitate NMS:
| Category | Examples |
|---|---|
| High-potency first-generation antipsychotics (highest risk) | Haloperidol, fluphenazine, thioxanthene derivatives |
| Low-potency first-generation | Chlorpromazine, thioridazine |
| Antiemetics | Metoclopramide, prochlorperazine, promethazine |
| Second-generation antipsychotics (lower, but real risk) | Olanzapine, risperidone, clozapine, aripiprazole, ziprasidone |
| Dopamine agonist withdrawal | Levodopa, dopamine agonists (Parkinson's disease patients) |
Second- and third-generation antipsychotics are associated with NMS, but fever and autonomic lability tend to be less prominent than with first-generation agents.
- Goldman-Cecil Medicine; Tintinalli's, p. 1251
Pathophysiology
NMS likely results from acute central dopamine D2 receptor blockade, particularly in:
- The nigrostriatal pathway - causing extreme extrapyramidal rigidity
- The hypothalamus - disrupting thermoregulation
- Possibly also direct toxic effects on muscle cell membranes
Some consider NMS the most extreme form of drug-induced parkinsonism (DIP). A D2 receptor gene polymorphism and predisposing factors (fatigue, dehydration, rapid dose escalation) may increase individual susceptibility.
- Stahl's Essential Psychopharmacology, p. 185
Clinical Features - The Classic Tetrad
NMS typically develops over 1-3 days, with altered mental status usually appearing first:
- Altered mental status - agitation progressing to stupor or coma
- "Lead-pipe" muscular rigidity - generalized, in all muscle groups; also cogwheel rigidity
- Hyperthermia - fever >38°C on at least two occasions; can be markedly elevated (>40°C)
- Sympathetic nervous system lability - hypertension, BP fluctuations, diaphoresis, tachycardia, tachypnea, urinary incontinence
Laboratory abnormalities:
- Elevated CK (up to 60,000 U/L) - cardinal finding
- Leukocytosis
- Elevated hepatic transaminases
- Myoglobinuria
- Elevated BUN/creatinine (from rhabdomyolysis-induced acute kidney injury)
- Decreased serum iron
- Metabolic acidosis, hyper- or hyponatremia
- Tintinalli's, p. 1252; Adams and Victor's, p. 1210
Diagnostic Criteria (2011 International Consensus)
Per the International Consensus Criteria (validated 2017), diagnosis requires:
Major features:
- Fever >38°C on at least two occasions
- Lead-pipe muscle rigidity
- Psychomotor slowing and altered mental status
- Sympathetic lability (2 or more of: elevated BP, BP fluctuation, diaphoresis, urinary incontinence)
- Recent dopamine antagonist exposure or dopamine agonist withdrawal
Minor features:
- CK >4x upper limit of normal or myoglobinuria
- Tachycardia / tachypnea
- Hypersalivation
- Tremor / muscle cramps
Exclusion: No other infectious, toxic, metabolic, or neurologic cause identified
A cut-off score of 74 on the consensus scoring system has sensitivity 69.6%, specificity 90.7%, and agreed with consultant diagnoses in 85.7% of cases.
- The Clozapine Handbook, p. 265
Differential Diagnosis
The most important conditions to distinguish:
| Feature | NMS | Serotonin Syndrome | Malignant Catatonia |
|---|---|---|---|
| Trigger | D2 antagonists / dopamine agonist withdrawal | Serotonergic agents | Medical/psychiatric/neurologic |
| Onset | 1-3 days | <12 hours | Days to weeks |
| Resolution | Days to weeks | <24 hours | Days to weeks |
| Rigidity | Lead-pipe, all groups | Less intense | Waxy/paratonic |
| Reflexes | Hyporeflexia | Hyperreflexia + clonus | Normal |
| Pupils | Normal | Dilated | Variable |
| Other | - | Myoclonus, diarrhea, shivering | Low serum iron is a risk factor |
Other DDx: Meningitis/encephalitis, heat stroke, lithium intoxication, anticholinergic poisoning, malignant hyperthermia (triggered by inhalation anesthetics - a distinct entity with ryanodine receptor mutations, though both respond to dantrolene).
Critical pitfall: Mistaking NMS for worsening psychosis and administering more antipsychotic.
- Goldman-Cecil Medicine, Table 402-4; Adams and Victor's, p. 1210
Treatment
Immediate Steps
- Discontinue all antipsychotics and potentiating drugs (anticholinergics, antihistamines, lithium)
- IV hydration - restore circulating volume, maintain urine output (prevent/treat myoglobinuria-induced AKI)
- External cooling - pharmacologic antipyretics (acetaminophen, NSAIDs) are NOT effective for NMS hyperthermia
- Sedation - benzodiazepine (lorazepam 1-2 mg IV q2-4h) to reduce agitation and sympathetic activity
- Airway protection - early intubation if hypersalivation, dysphagia, decreased airway reflexes, acidosis, or hypoxia
When intubating: use non-depolarizing agents (e.g., rocuronium) - avoid succinylcholine
Specific Pharmacotherapy
| Agent | Mechanism | Dosing | Notes |
|---|---|---|---|
| Bromocriptine | Dopamine agonist (central) | 2.5-5 mg PO TID-QID (up to 20 mg TID) | Reduces fever and rigidity; only oral form available; may cause hypotension, vomiting, worsening psychosis |
| Dantrolene | Direct skeletal muscle relaxant | 1.0-2.5 mg/kg IV load, then 1 mg/kg IV q6h; or 0.25-3.0 mg IV | For severe/pronounced rigidity; avoid concurrent calcium (risk of cardiovascular collapse) |
| Amantadine | Dopaminergic | 100 mg PO TID | Alternative to bromocriptine |
| Lorazepam | Benzodiazepine | 1-2 mg IV q2-4h | First-line sedation; may be enough in mild cases |
- Bromocriptine should be started early when consciousness first changes and temperature is rising - it can terminate the syndrome within hours at that stage
- No pharmacotherapy has been shown superior to supportive care alone in controlled trials; the evidence base is case reports and series
Complications
Most deaths result from profound muscle rigidity leading to: rhabdomyolysis, acute kidney injury, respiratory failure, DIC, cardiovascular collapse, hypoxemic-ischemic brain injury.
- Tintinalli's, p. 1253; Adams and Victor's, p. 1210
Rechallenge & Recurrence
- Avoid restarting the offending neuroleptic until NMS has fully resolved
- When rechallenge is necessary (e.g., severe psychiatric illness), use a lower-potency agent from a different class, start at a low dose, and wait at least 2 weeks after resolution
- In clozapine-associated NMS (where clozapine monotherapy is rarely implicated), rechallenge was successful in 7/7 reported cases
- Note: Abrupt clozapine discontinuation causes cholinergic rebound, which exacerbates both the mental status changes and extrapyramidal symptoms of NMS - manage accordingly
- The Clozapine Handbook, p. 265-266
Recent Literature (2024)
A 2024 review in NEJM by Wijdicks & Ropper provides an updated clinical overview of NMS (PMID: 39321364). The core diagnostic and treatment framework remains consistent with the above, with ongoing recognition that atypical antipsychotics produce a somewhat attenuated phenotype compared to classic first-generation NMS.
Csf protein is high in this pt.!
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
This is a really important clinical point. Here is the full picture:
Elevated CSF Protein in a Suspected NMS Patient - What It Means
CSF in "True" NMS is Normal
This is the key teaching point: classic NMS does NOT cause CSF abnormalities. The CSF in NMS is typically completely normal - no pleocytosis, no elevated protein, no elevated glucose. The most specific lab finding in NMS is the markedly elevated serum CK, not any CSF change.
"The most specific laboratory abnormality in these patients is a markedly elevated creatine kinase level." - Goldman-Cecil Medicine, p. 4004
So What Does Elevated CSF Protein Tell You?
Elevated CSF protein in this clinical picture - fever + rigidity + altered mental status (which looks like NMS) - should immediately redirect your diagnosis. It points toward conditions that genuinely cause CSF inflammation. The major possibilities:
1. Viral / Infective Encephalitis (most important)
- HSV encephalitis, West Nile virus, enteroviral meningitis, CMV, EBV
- CSF: elevated protein, lymphocytic pleocytosis, normal to mildly low glucose
- Can mimic NMS perfectly in a patient on antipsychotics
- Real case from Kaplan & Sadock: A 58-year-old man on haloperidol + clozapine + lithium presented with fever, rigidity, tachycardia, altered mental status - NMS suspected, medications stopped. CSF showed WBC 54/µL (lymphocytes) + protein 71 mg/dL + positive West Nile virus serology. It was viral encephalitis, not NMS at all.
- This is the classic "NMS mimic" trap - the patient is on a neuroleptic, so NMS gets blamed, but the CSF tells the true story.
2. Anti-NMDAR Encephalitis (and other Autoimmune Encephalitis)
- Especially common in young women
- Often preceded by viral prodrome (fever, headache)
- Presents with: psychosis, abnormal movements, seizures, autonomic instability, fever
- Patients are frequently started on antipsychotics for the psychiatric symptoms, and then the rigidity and fever get attributed to NMS
- CSF: mild protein elevation, lymphocytic pleocytosis, may have oligoclonal bands
- Bradley & Daroff's Neurology specifically warns: "Some patients with autoimmune encephalitis, especially those with NMDAR antibodies, experience fever and abnormal movements erroneously ascribed to the use of antipsychotic medication"
- Action: Send CSF + serum for autoimmune encephalitis antibody panel (anti-NMDAR, anti-LGI1, anti-CASPR2, anti-GABA-B, etc.)
3. Bacterial Meningitis / Septic Meningitis
- CSF protein markedly elevated (often >100 mg/dL), neutrophilic pleocytosis, low glucose
- Less likely to be confused with NMS but must be excluded
4. Malignant Catatonia
- A related but distinct syndrome - not always caused by drug exposure
- Can have some CSF abnormalities if an underlying autoimmune or inflammatory cause is driving the catatonia
- EEG typically shows diffuse slowing; CSF may be abnormal if encephalitis is the underlying cause
Practical Action When CSF Protein is Elevated
| Step | Action |
|---|---|
| Do NOT assume it's NMS | NMS has normal CSF - elevated protein is an exclusionary red flag |
| Send CSF studies | Cell count, glucose, Gram stain/culture, HSV PCR, other viral PCR, autoimmune encephalitis panel (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPAR, DPPX) |
| MRI brain with FLAIR | Look for temporal lobe signal (HSV), orbitofrontal involvement; autoimmune encephalitis may show FLAIR changes |
| EEG | Nonconvulsive status epilepticus, diffuse slowing, extreme delta brush (anti-NMDAR) |
| Tumor workup | If autoimmune encephalitis is confirmed, look for teratoma (in young women with NMDAR), thymoma, lung/breast cancer |
| Still stop the antipsychotic | Until the diagnosis is clarified - either to treat possible NMS, or because antipsychotics are not safe in encephalitis |
| Consider empiric HSV treatment | If encephalitis not yet excluded - give IV acyclovir while awaiting PCR |
Bottom Line
Elevated CSF protein in a patient with the NMS phenotype (fever + rigidity + altered mental status + autonomic instability) is not consistent with NMS itself - it demands a diagnosis of encephalitis until proven otherwise, most urgently HSV and anti-NMDAR autoimmune encephalitis. This is one of the most dangerous diagnostic pitfalls in neuropsychiatry.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Bradley & Daroff's Neurology; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.